Gain Therapeutics (GANX) Receivables (2020 - 2026)

Gain Therapeutics has reported Receivables for 6 years, with the latest figure at $821212.0 in Q2 2026.

• On a quarterly basis, Receivables fell 25.1% year-over-year to $821212.0 in Q2 2026; TTM through Jun 2026 was $821212.0, a 25.1% decrease from a year earlier, with the FY2025 full-year figure at $622992.0, up 25.94% from the prior year.
• Receivables was $821212.0 for Q2 2026 at Gain Therapeutics, up from $763606.0 in the prior quarter.
• The five-year high for Receivables was $1.1 million in Q2 2025, with the low at $87430.0 in Q4 2022.
• Average Receivables over 4 years is $630295.2, with a median of $630976.5 recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Receivables gained 25.94% in 2025, then declined 25.1% in 2026.
• Over 4 years, Receivables stood at $87430.0 in 2022, then soared by 465.81% to $494684.0 in 2024, then climbed by 25.94% to $622992.0 in 2025, then jumped by 31.82% to $821212.0 in 2026.
• The last three Receivables figures came in at $821212.0 (Q2 2026), $763606.0 (Q1 2026), and $622992.0 (Q4 2025), per Business Quant data.